Venus Remedies has received approval from Corporate Debt Restructuring Cell (CDR Cell) for its CDR proposal. Consequently, the moratorium period of the repayments of the principal borrowings has been extended to two years with effect from April 1. 2014.
The lenders have also sanctioned financial assistance towards repayment commitments of FCCBs of the Company, due in February, 2015. With this, the company has concluded its financial restructuring. The implementation process of the CDR is underway.
Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1652.20 |
| Dr. Reddys Lab | 1223.45 |
| Cipla | 1213.90 |
| Zydus Lifesciences | 925.20 |
| Lupin | 2325.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: